INVESTOR RELATIONS
KEY FIGURES
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
PRESS RELEASES
PERMIRA funds to partner with Marcucci family to invest in Kedrion Biopharma and Bio Products Laboratory
Kedrion maintains its Revenues and Ebitda in line compared to previous year
Kedrion announces the closing of the first part of the transaction with Liminal
FINANCIAL REPORTS
CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2021
CONSOLIDATED FIRST HALF RESULTS 2021
Download
CONSOLIDATED FINANCIAL STATEMENTS Q1 2021
DOWNLOAD
CONSOLIDATED FINANCIAL STATEMENTS 2020
Download
CONSOLIDATED FIRST HALF RESULTS 2020
Download
CONSOLIDATED FINANCIAL STATEMENTS 2019
Download
CONSOLIDATED FIRST HALF RESULTS 2019
Download
KEDRION NOTES
CONTACT & EMAIL ALERTS
Subscribe to the service in order to receive our news
